FDA Vaccinia-Complication Draft Guidance Emphasizes Data Collection Systems
This article was originally published in The Pink Sheet Daily
Executive Summary
The second of three guidances on FDA's counter-terrorism plans strongly encourages early communication with the agency. Guidance on smallpox drug development is forthcoming.
You may also be interested in...
Bavarian Nordic Smallpox Vaccine Is Imvamune; U.S. Trials To Commence This Year
The company expects to begin large-scale production by mid-2005 and plans to seek a U.S. commercialization partner for the third-generation smallpox vaccine.
Bavarian Nordic Smallpox Vaccine Is Imvamune; U.S. Trials To Commence This Year
The company expects to begin large-scale production by mid-2005 and plans to seek a U.S. commercialization partner for the third-generation smallpox vaccine.
Biodefense R&D: First Anthrax Vaccine Could Enter Phase II In 2004
An HHS contract is supporting the development of VaxGen's recombinant anthrax vaccine. Acambis/Baxter's second-generation smallpox vaccine ACAM-2000 is in Phase II.